Teva Pharmaceutical Industries Ltd. announced the launch of the generic equivalent to Pulmicort Respules® (budesonide inhalation suspension), 1 mg/2 mL, in the United States.
Budesonide inhalation suspension is an inhaled corticosteroid medicine. It is a long-term maintenance medicine used to control and prevent asthma symptoms in children ages 12 months to 8 years. Budesonide inhalation suspension helps to reduce swelling and inflammation in the lungs, and also helps keep the airways open to reduce asthma symptoms.
With the addition of this new strength of budesonide inhalation suspension, Teva the leader of the product market in total prescriptions of budesonide inhalation suspension now offers the complete family of all strengths including, 0.25 mg/2 mL, 0.5 mg/2 mL, and 1 mg/2 mL.
Pulmicort Respules® (budesonide inhalation suspension), had annual sales of approximately $217 million in the United States, according to IMS data as of November 2015.
